MLTX (MoonLake Immunotherapeutics) Marketable Securities: $59.43 Mil (As of Mar. 2026)


MLTX MoonLake Immunotherapeutics MLTX
28 GF Score
Price $19.07
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Marketable Securities?

MoonLake Immunotherapeutics MLTX -0.37% 28 Marketable Securities is $59.43 Mil as of Mar. 2026. GuruFocus rates MLTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. MoonLake Immunotherapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $59.43 Mil.

MoonLake Immunotherapeutics's annual Marketable Securities increased from Dec. 2023 ($59.84 Mil) to Dec. 2024 ($267.60 Mil) but then declined from Dec. 2024 ($267.60 Mil) to Dec. 2025 ($59.45 Mil).

MoonLake Immunotherapeutics  (NAS:MLTX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

MoonLake Immunotherapeutics Marketable Securities Related Terms

MoonLake Immunotherapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Marketable Securities Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 32.61 59.84 267.60 59.45

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.56 118.40 29.74 59.45 59.43
MLTX
28GF Score
MoonLake Immunotherapeutics MLTX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $59.43 Mil mean?
MoonLake Immunotherapeutics (MLTX) has a Marketable Securities of $59.43 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on MoonLake Immunotherapeutics and its competitors.
Is MoonLake Immunotherapeutics' Marketable Securities too high?
MoonLake Immunotherapeutics' current Marketable Securities is $59.43 Mil. Overall, MoonLake Immunotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Marketable Securities compare to FTRE and SEPN?
MoonLake Immunotherapeutics' Marketable Securities of $59.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current Marketable Securities is $59.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Marketable Securities of $59.43 Mil. The current Marketable Securities is $59.43 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Marketable Securities is $59.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
28GF Score

Get the complete analysis for MLTX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.07
Price